The Microformulator-replicated olaparib PK monotherapy condition gave greater efficacy in vitro than was observed in vivo; this may relate to greater tumour cell exposure in a 2D monolayer than in a 3D tumour xenograft or greater sensitivity to PARP inhibition. The gene discussed is PARP1; the disease is neoplasm.